The U.S. imposition of 100% tariffs on patented pharmaceutical imports in 2025 presents both a threat and an opportunity for India's pharmaceutical industry. Critically analyse.

Announced in September 2025 and operationalised under Section 232 of the U.S. Trade Expansion Act, the 100% ad valorem tariff applies to patented pharmaceuticals, while generics and biosimilars remain exempt [1][2]. For India, therefore, the shock is less an immediate export loss than a structural constraint on its future direction.

The threat dimension

• Concentration risk: the U.S. absorbs about 34% of India's pharmaceutical exports of $30.47 billion (FY2025), Europe another 19% — leaving policy leverage heavily one-sided [4].
• Legal durability: routed through a national-security investigation, the measure sidesteps ordinary trade-negotiation and WTO dispute timelines, and its scope can be widened by proclamation [2][3].
• Discriminatory tiering: EU, Japan, Korea and Switzerland face only 15%, and firms signing pricing and onshoring agreements pay 0% — India, without such an arrangement, bears the residual full rate [1].
• Value-chain penalty: the Economic Survey's stated shift from volume to complex generics, biosimilars and patented drugs is precisely the segment now taxed [5].

The opportunity dimension

• The generics carve-out protects India's core business and improves its relative price advantage as branded drugs turn costlier in the U.S. [1].
• Onshoring and pricing agreements offer a negotiated route to zero duty for larger Indian firms [1].
• It accelerates market diversification — exports already reach 191 countries, and Europe, Africa and Latin America can absorb more [5].
• PLI for Pharmaceuticals (₹15,000 crore) and PLI for Bulk Drugs (₹6,940 crore, 41 bulk drugs) support both the move up the value chain and reduced API import dependence [6].

Critically, the opportunity is conditional: the exemption is administratively revocable, and onshoring shifts investment away from India.

India's response should combine bilateral negotiation for durable generic exemption, faster PLI implementation, and stronger quality compliance — converting an external shock into the discipline needed to become an innovation-led pharmacy of the world.